| Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 8504497 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Staphylokinase (STA), a protein with known profibrinolytic properties, is produced by transduced Staphylococcus aureus strains. In experimental animal models, recombinant staphylokinase (STAR) is less immunogenic and more active toward platelet-rich arterial blood clots than streptokinase. METHODS AND RESULTS: In the present study, 10 mg STAR given intravenously over 30 minutes was found to induce angiographically documented coronary artery recanalization within 40 minutes in four of five patients with acute myocardial infarction. Plasma fibrinogen and alpha 2-antiplasmin levels were unaffected, and allergic reactions were not observed. Postinfusion disappearance of STAR antigen followed a biphasic mode with a t1/2 alpha of 6.3 +/- 0.6 minutes (mean +/- SD) and a t1/2 beta of 37 +/- 15 minutes, corresponding to a plasma clearance of 270 +/- 100 mL/min. Neutralizing antibodies against STAR could not be demonstrated at baseline and up to 6 days after infusion, but STAR neutralizing activity, which did not cross-react with streptokinase, was consistently demonstrable in plasma at 14-35 days. CONCLUSIONS: STAR can induce clot-selective coronary thrombolysis in patients with evolving myocardial infarction without concomitant induction of a systemic lytic state. STAR, a small protein that can be easily produced by recombinant DNA technology, may therefore offer promise for thrombolytic therapy in patients with thromboembolic disease. |
| | |
Authors:
|
D Collen; F Van de Werf |
Related Documents
:
|
2868337 - Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. gru... 3315587 - Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute m... 8159597 - Febrile reaction associated with urokinase. 3717017 - High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial inf... 3669277 - Prognosis of dilated cardiomyopathy: from a retrospective to a prospective study employ... 10794747 - Cardiac troponins i and t are biological markers of left ventricular dysfunction in sep... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Circulation Volume: 87 ISSN: 0009-7322 ISO Abbreviation: Circulation Publication Date: 1993 Jun |
Date Detail:
|
Created Date: 1993-07-02 Completed Date: 1993-07-02 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1850-3 Citation Subset: AIM; IM |
Affiliation:
|
Center for Thrombosis and Vascular Research, University of Leuven, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Coronary Angiography Coronary Vessels / physiopathology Female Humans Male Metalloendopeptidases / pharmacokinetics, therapeutic use* Middle Aged Myocardial Infarction / drug therapy*, radiography Pilot Projects Recombinant Proteins / pharmacokinetics, therapeutic use Thrombolytic Therapy* Time Factors Vascular Patency / physiology |
| Chemical | |
Reg. No./Substance:
|
0/Recombinant Proteins; EC 3.4.24.-/Metalloendopeptidases; EC 3.4.24.29/auR protein, Staphylococcus aureus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Myocardial infarct size can be estimated from serial plasma myoglobin measurements within 4 hours of...
Next Document: X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dyst...